List of quality statements

List of quality statements

Statement 1. Adults with a baseline total cholesterol above 7.5 mmol/l are assessed for a clinical diagnosis of familial hypercholesterolaemia (FH).

Statement 2. People with a clinical diagnosis of familial hypercholesterolaemia (FH) are referred for specialist assessment.

Statement 3. People with a clinical diagnosis of familial hypercholesterolaemia (FH) are offered DNA testing as part of a specialist assessment.

Statement 4. Children at risk of familial hypercholesterolaemia (FH) are offered diagnostic tests by the age of 10 years.

Statement 5. Relatives of people with a confirmed diagnosis of monogenic familial hypercholesterolaemia (FH) are offered DNA testing through a nationwide, systematic cascade process.

Statement 6. Adults with familial hypercholesterolaemia (FH) receive lipid‑modifying drug treatment to reduce LDL‑C concentration by more than 50% from baseline.

Statement 7. Children with familial hypercholesterolaemia (FH) are assessed for lipid‑modifying drug treatment by a specialist with expertise in FH in a child‑focused setting by the age of 10 years.

Statement 8. People with familial hypercholesterolaemia (FH) are offered a structured review at least annually.